Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400)
Brand Names: Core Values Eye Drops Dry Eye Relief
Methodology & AI Transparency ⓘ
Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within the Non-Standardized Chemical Allergen category, Core Values Eye Drops Dry Eye Relief provides branded delivery of active moiety Glycerin, Hypromellose, Polyethylene Glycol 400 (cross-referenced at /meds/glycerin-hypromellose-polyethylene-glycol-400) (registered by Liberty Procurement Co.
- 2 Real-world patient consensus: Registered under RxNorm 259581-B63940035 and SPL 2025-12-30, pairing Core Values Eye Drops Dry Eye Relief packaging with active ingredient Glycerin, Hypromellose, Polyethylene Glycol 400.
- 3 Typical cash cost range: Public pharmacy ledger: $15.96 low cash benchmark vs. $42.29 chain retail average ($0.1036/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) tolerability events: application-site irritation (4.7%), nausea (9.2%), headache (7.4%).
Ask our AI Specialists anything about Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400)
Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) Mechanism, CYP450 Pathways & DailyMed Monograph
Within the Non-Standardized Chemical Allergen category, Core Values Eye Drops Dry Eye Relief provides branded delivery of active moiety Glycerin, Hypromellose, Polyethylene Glycol 400 (cross-referenced at /meds/glycerin-hypromellose-polyethylene-glycol-400) (registered by Liberty Procurement Co. Inc.; NDC 63940-035, 55651-115). Characterized by .2 g/100mL / .2 g/100mL Solution/ Drops; 1 g/100mL / .2 g/100mL Solution under 2025-12-30 SPL documentation, Core Values Eye Drops Dry Eye Relief targets Uses for the temporary relief of burning and irritation due to dryness of the eye for protection against further irritation
Through its Glycerin, Hypromellose, Polyethylene Glycol 400 active moiety, Core Values Eye Drops Dry Eye Relief exerts non-standardized chemical allergen activity with class-characteristic hepatorenal disposition. Registered under NDC 63940-035, 55651-115 (registered by Liberty Procurement Co. Inc.; effective 2025-12-30), the .2 g/100mL / .2 g/100mL Solution/ Drops; 1 g/100mL / .2 g/100mL Solution presentation ensures reproducible pharmacokinetic release profiles documented in federal RxNorm (259581-B63940035) and CMS NADAC ($0.1036/unit) ledgers.
Following administration (.2 g/100mL / .2 g/100mL Solution/ Drops), Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) achieves F ≈ 73%–85% systemic availability after standard oral Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) administration bioavailability and time to peak concentration spans 1 to 3 hrs under core values eye drops dry eye relief (glycerin, hypromellose, polyethylene glycol 400) maintenance onset, governed by a Terminal t½ estimated at 4–12 hrs depending on renal/hepatic reserve (Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400)) terminal half-life through mixed metabolic conjugation and unchanged urinary excretion across core values eye drops dry eye relief (glycerin, hypromellose, polyethylene glycol 400) regimens.
Before initiating Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) at .2 g/100mL / .2 g/100mL Solution/ Drops, clinical safety checklists rule out severe drug-induced hypersensitivity to glycerin, hypromellose, polyethylene glycol 400 or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2025-12-30 for core values eye drops dry eye relief (glycerin, hypromellose, polyethylene glycol 400). Logged tolerability patterns center on nausea (9.2% of reports), headache (7.4% of reports), dizziness (6.3% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) (non-standardized chemical allergen).
Botanical enzyme modulators may alter oral first-pass exposure of Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Glycerin, Hypromellose, Polyethylene Glycol 400 or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2025-12-30 for Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400)
Logged Side-Effect Incidence (14 Reports)
Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Exogenous melatonin on: What a 284-Participant Study Found Since 15 of the 17 studies enrolled healthy subjects or people with no relevant medical condition other than trouble sleeping, the analysis was also done including only these 15 studies. Sleep medicine reviews • 2005-02-15 • Meta-Analysis | N = 284 | 97/100 | PMID 15649737 ↗ |
| New Insights on Impact of subclinical hypothyroidism on core reproductive hormones and ovarian: What a 3,114-Participant Study Found Current evidence shows no significant differences in FSH, LH, estradiol, or total testosterone levels between SCH and euthyroid PCOS controls, while the evidence for prolactin. Frontiers in endocrinology • 2026-01-15 • Meta-Analysis | N = 3,114 | 94/100 | PMID 42798498 ↗ |
| New Insights on Health-related quality of life scores of metastatic pancreatic cancer patients: What a 466-Participant Study Found This is the first study to systematically derive EORTC QLQ-C30 reference values for mPC. BMC cancer • 2022-05-20 • Phase III Randomized Trial | N = 466 | 93/100 | PMID 35596182 ↗ |
| New Insights on Early toxicity of moderately hypofractionated radiation therapy in breast cancer: What a 1,265-Participant Study Found Early AEs were mild and do not raise safety concerns for 3-week-RT in women receiving nodal RT. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2025-06-15 • Phase III Randomized Trial | N = 1,265 | 90/100 | PMID 40097073 ↗ |
| New Insights on 21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter: What a 8,916-Participant Study Found RS is an independent measure for BCSS and recurrence prognoses relative to OS in early-stage breast cancer. Journal of the National Comprehensive Cancer Network : JNCCN • 2024-07-17 • Phase III Randomized Trial | N = 8,916 | 90/100 | PMID 39019060 ↗ |
Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1036/unit (~$3.11/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $42.29 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $15.96 / mo | View logs ↓ |
Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) RxNorm Concept ID | 259581-B63940035 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1036 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $42.29 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $15.96 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 81.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) integrating DailyMed SPL (2025-12-30), CMS NADAC ($0.1036/unit), and 14 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Core Values Eye Drops Dry Eye Relief (Glycerin, Hypromellose, Polyethylene Glycol 400) community threads and patient logs by age, biological sex, dosage, and treatment duration.